AbbVie Inc. / DJS Antibodies Ltd.

Idiopathic Pulmonary Fibrosis (IPF)

30K US cases/yr · $3.5B Global IPF therapeutics market (2022)

Disease Overview

Idiopathic pulmonary fibrosis is a chronic, progressive, fibrosing interstitial lung disease of unknown etiology characterized by progressive scarring of lung parenchyma, declining FVC, and a median survival of 3-5 years from diagnosis without lung transplant. U.S. prevalence is estimated at 100,000-200,000, with incidence of roughly 30,000-40,000 new cases per year. Disease primarily affects adults over 60 with a male predominance. Two FDA-approved antifibrotics (pirfenidone, nintedanib) slow FVC decline by approximately 50% but neither halts progression nor reverses fibrosis, leaving substantial residual unmet need. Acute exacerbations carry catastrophic mortality, and lung transplant remains the only intervention that prolongs life materially. The commercial market is meaningful but has been frustrated by serial Phase 3 failures of follow-on agents, including PRM-151 (Roche), pamrevlumab (FibroGen), zinpentraxin (Roche), and ziritaxestat (Galapagos). LPAR1 antagonism, the mechanism of DJS-002, has prior validation via BMS-986020 (early Phase 2 hepatic safety signal halted) and revisited by Bristol's BMS-986278 (Phase 2 positive readout 2023). Payer coverage of antifibrotics is established but step-edited through prior authorization.

Competitive Landscape

The IPF therapeutic landscape is anchored by two genericized or branded antifibrotics with no successful class disruption since 2014. Pirfenidone (Esbriet, Roche; multiple generics post-2022) and nintedanib (Ofev, Boehringer Ingelheim) are the standard-of-care antifibrotics; both slow FVC decline by approximately 50% but neither halts progression nor reverses fibrosis. The Phase 2/3 LPAR1 antagonism franchise is the most credible new mechanism. BMS-986278 (Bristol Myers Squibb) reported a positive Phase 2 readout in late 2023 showing reduced FVC decline and has advanced to Phase 3. DJS-002 (preclinical, AbbVie via this acquisition) is a first-in-class LPAR1 antagonist antibody differentiated from small-molecule competitors by potential subcutaneous dosing. Other late-stage entrants include nerandomilast (BI 1015550, PDE4B inhibitor, Boehringer Ingelheim), which delivered a positive FIBRONEER-IPF Phase 3 readout in 2024, and PLN-74809/bexotegrast (αvβ6 integrin inhibitor, Pliant Therapeutics) in Phase 2b. Failed late-stage assets that frame the risk profile include zinpentraxin alfa (Roche), pamrevlumab (FibroGen), and ziritaxestat (Galapagos). AbbVie's bet on DJS-002 is a long-cycle, preclinical-stage immunology pipeline play.